Close Menu

Breaking News

MicroGen Dx's Texas-based lab is the only commercial laboratory in the US offering sputum testing for SARS-CoV-2.

The approach deconvolutes admixed individuals' ancestries and develops polygenic risk scores based on each component that can then be combined.

After validating its pathogen detection platform for multiple viruses, the firm aims to initially offer a point-of-care diagnostic testing panel by the third quarter.

News items for the week of March 30, 2020.

Women with breast cancer from Peru, Mexico, or Colombia who had greater Indigenous American ancestry were more likely to have HER2-positive tumors.

The test, run on the BD Max system, allows hospitals to diagnose SARS-CoV-2 on site and receive results in less than three hours.

The firm believes that its molecular assay for the laboratory will help ease some of the supply chain issues hampering test rollout during the pandemic.

The test, developed by the firms in six weeks, is part of a viral respiratory panel and runs on Bosch's point-of-care Vivalytic system.

The researchers identified rare germline loss-of-function variants across the ELP1 gene in 14 percent of pediatric patients in a medulloblastoma subgroup.

Credo Diagnostics recently received the CE mark for the coronavirus test, which can provide results in 20 minutes.

The firms plan to discover and develop fully human neutralizing antibodies that target the SARS-CoV-2 virus, combining Adaptive's and Amgen's respective expertise.

Axxam said it will use the CRISPR technology to support the development of customized cell-based assays for targets and molecular pathways of interest.

The company is also participating in a study, being conducted at Hannover Medical School, investigating the genetics of susceptibility to COVID-19.

The investment bank said that Exact's Cologuard test continues to gain market share, and that its alternatives are largely invasive and inferior.

The test is designed to detect SARS-CoV-2 nucleic acid in nasopharyngeal and oropharyngeal swab specimens from individuals suspected of having COVID-19.

The company said the revenue increase is driven primarily by growth in the life science segment due to high demand for SARS-CoV-2 molecular products.

The company withdrew its 2020 revenue guidance and said it expects to report revenues of more than $63 million in the quarter ended March 31.

The firm had been in stealth mode, but hopes to now attract partners to further commercialize its system for decentralized testing.

The GenomeWeb Index fared better than its benchmark counterparts in March, but still fell more than 4 percent.

A two-stage, case-control genetic association study has implicated rare variants in the PTGIS gene in idiopathic pulmonary arterial hypertension susceptibility.

The funding round was led by new investor Co-Win Ventures, with additional investment by existing investors Tramway Partners, Cottonwood Technology Fund, and Sun Mountain Capital.

The deals are with institutional investors and more than 1 million American Depositary Shares will be offered at A$1.75 per ADS.

Protein profiling on ancient dental enamel samples suggests Homo antecessor was part of a lineage that split from that leading to modern humans and Neanderthals.

Pages

A German shepherd called Nala has had her genome sequenced.

A coronavirus serology test garners Emergency Use Authorization from the US Food and Drug Administration, but the Los Angeles Times asks: how will tests like that be used?

Certain gene variants in conjunction with a healthy lifestyle may keep brains young, according to New Scientist.

In Science this week: increased CD8 T cell density and increased IFN-gamma response may indicate metastatic prostate cancer patients who will respond to immune checkpoint blockade therapy.